Probiotics and barrier function in colitis

Gut

Volumn 54, Issue 7, 2005, Pages 898-900

  Gionchetti, P ^a,b   Lammers, K M ^a   Rizzello, F ^a   Campieri, M ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PROBIOTIC AGENT;

BIFIDOBACTERIUM; COLITIS; HUMAN; INTESTINE FLORA; INTESTINE MUCOSA; LACTOBACILLUS; MICROBIAL COLONIZATION; NONHUMAN; NOTE; PRIORITY JOURNAL; SACCHAROMYCES BOULARDII; STREPTOCOCCUS;

ANTIBIOSIS; COLITIS, ULCERATIVE; HUMANS; INTESTINAL ABSORPTION; INTESTINAL MUCOSA; PROBIOTICS;

EID: 21044455300     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2004.060640     Document Type: Note

References (31)

1. Guarner F, Casellas F, Borruel N, et al. Role of microecology in chronic inflammatory bowel diseases. Eur J Clin Nutr 2002;56:S34-8.
2. Campieri M, Gionchetti P. Probiotics in inflammatory bowel disease: new insight to pathogenesis or a possible therapeutic alternative? Gastroenterology 1999;116:1246-9.
3. Schaafsma G. State of the art concerning probiotic strains in milk products. IDF Nutr Newsl 1996;5:23-4.
4. Fabia R, Ar'rajab A, Johansson M-L, et al. The effect of exogenous administration of Lactobacillus reuterii R2LC and oat fiber on acetic acid-induced colitis in the rat. Scand J Gastroenterol 1993;28:155-62.
5. Madsen KL, Tavernini MM, Doyle JSG, et al. Lactobacillus sp prevents development of enterocolitis in interleukin-10 gene-deficient mice. Gastroenterology 1999;116:1107-14.
6. Schultz M, Veitkamp C, Dieleman LA, et al. Lactobacillus plantarum 299V in the treatment and prevention of spontaneous colitis in interleukin-10 deficient mice. Inflamm Bowel Dis 2002;8:71-80.
7. Shibolet O, Karmeli F, Eliakim R, et al. Variable response to probiotics in two models of experimental colitis in rats. Inflamm Bowel Dis 2002;8:399-408.
8. Gionchetti P, Rizzello F, Venturi A, et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 2000;119:305-9.
9. Mimura T, Rizzello F, Helwig U, et al. Once daily high dose probiotic therapy for maintaining remission in recurrent or refractory pouchitis. Gut 2004;53:108-14.
10. Gionchetti P, Rizzello F, Venturi A, et al. Prophylaxis of pouchitis onset with probiotic therapy: a double blind, placebo controlled trial. Gastroenterology 2003;124:1202-9.
11. Kruis W, Fric P, Pokrotnieks J, et al. Maintaining remission of ulcerative colitis with Escherichia Coli Nissle 1917 is as effective as with standard mesalazine. Gut 2004;53:1617-23.
12. Venturi A, Gionchetti P, Rizzello F, et al. Impact on the faecal flora composition of a new probiotic preparation. Preliminary data on maintenance treatment of patients with ulcerative colitis (UC) intolerant or allergic to 5-aminosalicylic acid (5 ASA). Aliment Pharmacol Ther 1999;13:1103-8.
13. Fedorak RN, Gionchetti P, Campieri M, et al. VSL#3 probiotic misture induces remission in patients with active ulcerative colitis. Gastroenterology 2003;124:A377.
14. Guslandi M, Mezzi G, Sorghi M, et al. Saccharomyces boulardii in maintenance treatment of Crohn's disease. Dig Dis Sci 2000;45:1462-4.
15. Prantera C, Scribano ML, Falasco G, et al. Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised contraolled trial with Lactobocillus GG. Gut, 2002;51:405-9.
16. Campieri M, Rizzello F, Venturi A, et al. Combination of antibiotic and probiotic treatment is efficacious in prophylaxis of post-operative recurrence of Crohn's disease: a randomised controlled study vs mesalazine. Gastroenterology 2000;118:A781.
17. Mack DR, Michail S, Wei S, et al. Probiotics inhibit enteropathogenic E. coli adeherence in vitro by inducing intestinal mucin gene expression. Am J Physiol 1999;276:G941-50.
18. Bernet MF, Brassart D, Neeser JR, et al. Lactobacillus acidophilus LA1 binds to cultured human intestinal cell lines and inhibits cell attachment and cell invasion by enterovirulent bacteria. Gut 1994;35:483-9.
19. Gewirtz AT, Liu Y, Sitaraman SV, et al. Intestinal epithelial pathobiology: past, present and future. Best Pract Res Clin Gastroenterol 2002;16:851-67.
20. Madsen K, Cornish A, Soper P, et al. Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology 2001;121:580-91.
21. Otte J-M, Podolsky DK. Functional modulation of enterocytes by gram-positive and gram-negative microorganisms. Am J Physiol Gastrointest Liver Physiol 2004;286:G613-26.
22. Lammers KM, Helwig U, Swennen E, et al. Effect of probiotic strains on interleukin 8 production by HT29/19A cells. Am J Gastroenterol 2002;97:1182-6.
23. Ulisse S, Gionchetti P, D'Alo S, et al. Expression of cytokines, inducible nitric oxide synthase, and matrix metalloproteinases in pouchitis: effects of probiotic treatment. Am J Gastroenterol 2001;96:2691-9.
24. Jijon H, Backer J, Diaz H, et al. DNA from probiotic bacteria modulates murine and human epithelial and immune function. Gastroenterology 2004;126:1358-73.
25. Hart AL, Lammers KM, Brigidi P, et al. Modulation of human dendritic cell phenotype and function by probiotic bacteria. Gut 2004;53:1602-9.
26. Lammers KM, Brigidi P, Vitali B, et al. Immunomodulatory effects of probiotic bacteria DNA: IL-1 and IL-10 response in human peripheral blood mononuclear cells. FEMS Immunol Med Microbiol 2003;38:165-72.
27. Willemsen LE, Koetsier MA, van Deventer SJ, et al. Short chain fatty acidsstimulate epithelial mucin 2 expression through differential effects on prostaglandin E(1) and E(2) production by intestinal myofibroblasts. Gut 2003;52:1442-7.
28. Petrof EO, Kojima K, Ropeleski MJ, et al. Probiotics inhibit nuclear factor-kappaB and induce heat shock proteins in colonic epithelial cells through proteasome inhibition. Gastroenterology 2004;127:1474-87.
29. Llopis M, Antolín M, Guarner F, et al. Mucosal colonisation with Lactobacillus casei mitigates barrier injury induced by exposure to trinitronbenzene sulphonic acid. Gut 2005;54:955-9.
30. Fasano A, Nataro JP. Intestinal epithelial tight junctions as targets far enteric bacteria-derived toxins. Adv Drug Deliv Rev 2004;56:795-807.
31. Schmitz H, Barmeyer C, Fromm H, et al. Altered tight junction structure contributes to the impaired epithelial barrier function in ulcerative colitis. Gastroenterology 1999;116:301-9.